Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,083 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,116
- Phase 1823
- Phase 1/Phase 2481
- Phase 3349
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,083 total
- NCT05850273Recruiting
Study how interferon works in blood cancer patients
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
Villejuif, Île-de-France RegionAges 18 years+ - NCT05909059RecruitingPhase 2
CAR-T therapy for people with kidney function problems
This study tests a type of immune treatment (CAR-T) in people whose kidneys are not working well, using chemotherapy first to help the CAR-T work. It may help people with certain blood cancers who have reduced kidney function to still receive CAR-T therapy safely.
Atlanta, GeorgiaAges 18 years+ - NCT05852717RecruitingPhase 2
Epcoritamab plus GDP chemotherapy for relapsed large B-cell lymphoma
This Phase 2 study tests epcoritamab combined with GDP chemotherapy to treat adults whose large B-cell lymphoma has come back or did not respond to prior treatment. It aims to improve how safely and effectively the disease can be controlled after standard chemotherapy.
Indianapolis, IndianaAges 18 years+ - NCT05853796Recruiting
Studying stroke warning signs in young adults
This observational study follows people ages 18–50 who had a first TIA (“mini-stroke”) or an acute ischemic stroke to better understand what happens after the event. It may help improve future care by tracking symptoms, imaging findings, and recovery over time.
Nijmegen, GelderlandAges 18–50 - NCT05853965RecruitingPhase 1/Phase 2
Study of belantamab plus venetoclax for relapsed myeloma
This Phase 1/2 trial tests whether combining belantamab mafodotin with venetoclax can treat multiple myeloma that has come back or did not respond (relapsed/refractory). It focuses on a specific myeloma subtype with a t(11;14) genetic marker, aiming to reduce the cancer in people who have already had several treatments.
Hamburg, HamAges 18 years+ - NCT05855083RecruitingPhase 2
Narsoplimab for high-risk TMA after bone marrow transplant
This trial studies the medicine narsoplimab in children who develop a serious complication called HSCT-TMA after a bone marrow transplant. It aims to improve safety and effectiveness for high-risk cases where the condition is ongoing or causing organ problems.
San Diego, CaliforniaAges 4 weeks–17 years - NCT05858424Recruiting
Day hospital program to improve young cancer survivors’ well-being
This study tests a structured “end-of-treatment” day hospital program to improve quality of life for adolescents and young adults after cancer treatment. You may be offered follow-up and supportive care soon after finishing treatment to help you feel better physically and emotionally.
LyonAges 15–25 - NCT05858814RecruitingPhase 1/Phase 2
Cell therapy to help prevent AML relapse after transplant
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
Hefei, AnhuiAges 18–70 - NCT05862012RecruitingPhase 1
Test drug ISB 2001 in multiple myeloma patients who relapsed
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
Palo Alto, CaliforniaAges 18 years+ - NCT05863234RecruitingPhase 1/Phase 2
Safety study for aggressive NK-cell leukemia patients
This early-phase study tests a new treatment approach for people with aggressive NK-cell leukemia, focusing mainly on safety. It may be offered to patients whose disease matches the study’s specific leukemia diagnosis rules.
Hiroshima, HiroshimaAges 18–70 - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Tucson, ArizonaAges Up to 26 years - NCT05866757Recruiting
Stopping maintenance treatment in multiple myeloma patients
This study looks at whether it is safe to stop “maintenance” treatment for people with multiple myeloma who have been in remission for a long time, including those who stopped early because of side effects. It tests whether stopping therapy affects disease control and helps reduce ongoing treatment burden.
Cork, IrelandAges 18 years+ - NCT05868395RecruitingPhase 2
Treating relapsed mantle cell lymphoma with three drug combination
This Phase 2 study tests how well polatuzumab combined with bendamustine and rituximab works for mantle cell lymphoma that has come back or not responded. It may help shrink tumors and improve disease control, especially after prior treatment with ibrutinib.
ViennaAges 18–100 - NCT05870475RecruitingPhase 2
Interferon plus ruxolitinib for hydroxyurea-resistant polycythemia vera
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
TianjinAges 18 years+ - NCT05870995RecruitingPhase 2
Chemo plus targeted conditioning for hard-to-treat AML
This trial studies a specific chemotherapy plan (called sequential CLAG-Ven) with a gentler “conditioning” treatment before a transplant or donor-based therapy. It may help people with refractory or quickly relapsing acute myeloid leukemia (AML) who have a suitable family or matched donor and can meet certain organ function and infection rules.
Shanghai, Shanghai MunicipalityAges 16–65 - NCT05871216Recruiting
Study of joint instability in people with loose joints
This trial is testing how to assess and manage joint instability in people who have unusually loose (hypermobile) joints. If you have moderate to severe loose joints, you may be able to join after screening checks like movement tests and health history.
BolognaAges 18–60 - NCT05873322Recruiting
Study glucose changes during steroid and asparaginase treatment
This study looks at how blood sugar changes in children and teens receiving treatment for ALL (a leukemia) or lymphoma. It focuses specifically on effects that may be caused by steroids and a medicine called PEG-asparaginase.
Aarhus NAges 1–17 - NCT05875805Recruiting
Telehealth planning for future care decisions
This trial tests a telehealth (video or phone) program that helps people with certain blood cancers plan their future care preferences. It may help you and your chosen support person communicate your wishes clearly, especially if you become too sick to speak for yourself.
Rochester, New YorkAges 60 years+ - NCT05876312RecruitingPhase 1/Phase 2
Study drug ADX-038 in healthy people and PNH patients
This early-stage study tests how safe and tolerable ADX-038 is, and how the body processes it, in healthy volunteers and in people with paroxysmal nocturnal hemoglobinuria (PNH). It may help researchers understand whether the drug works safely for PNH patients and identify the right dosing.
Brisbane, QueenslandAges 18 years+ - NCT05876923Recruiting
Exercise study for immune changes in indolent blood cancers
This study looks at how an exercise program may change parts of the immune system in people with slow-growing (indolent) non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL/SLL). It may help researchers understand which immune changes could be important for your condition.
Scottsdale, ArizonaAges 18–80 - NCT05880043RecruitingPhase 1/Phase 2
IV NK cell treatment for advanced cancers that returned
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
SeoulAges 19 years+ - NCT05881447Recruiting
Study kidney disease patterns in people in Tanzania
This study looks at how common chronic kidney disease is, how it develops over time, and what risk factors are linked to it. It may help improve how kidney disease is recognized and managed in your community.
Bagamoyo, Coast RegionAges 18–99 - NCT05882175Recruiting
Checking how well an index predicts blood cancer care
This trial looks at how well a measurement called the OHI Index works for people with blood cancers. It may help doctors better assess risk or needs, but it mainly focuses on validating the tool rather than testing a new drug.
Kfar SabaAges 18 years+ - NCT05882773Recruiting
Registry for adults with certain blood cancers
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
Hong KongAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,083 recruiting hematology studies from the U.S. registry right now, out of 7,730 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.